300970 华绿生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-2.9791.9855.3251.36216.719
总资产报酬率 ROA (%)-2.1291.4814.0581.02012.142
投入资产回报率 ROIC (%)-2.3941.6444.4121.11613.644

边际利润分析
销售毛利率 (%)0.37113.52216.3206.65727.284
营业利润率 (%)-9.7952.72710.7672.94322.048
息税前利润/营业总收入 (%)-9.6932.6619.3761.14321.958
净利润/营业总收入 (%)-9.7962.64710.3332.81621.695

收益指标分析
经营活动净收益/利润总额(%)101.762140.93885.12913.34492.268
价值变动净收益/利润总额(%)-0.1911.3905.25413.4241.495
营业外收支净额/利润总额(%)0.008-3.021-1.175-1.349-1.513

偿债能力分析
流动比率 (X)2.6162.6863.8375.3512.459
速动比率 (X)1.7151.8812.9874.7241.845
资产负债率 (%)28.98526.00523.11823.3900.269
带息债务/全部投入资本 (%)13.68410.08813.94014.55714.212
股东权益/带息债务 (%)574.180814.013599.162564.466573.845
股东权益/负债合计 (%)241.131280.865329.901325.557270.294
利息保障倍数 (X)-94.613193.875-7.407-0.64992.205

营运能力分析
应收账款周转天数 (天)6.8405.62811.83316.3407.114
存货周转天数 (天)72.18372.14175.84363.96260.760